Last updated: November 2026. Reviewed against American Academy of Dermatology (AAD) guidance, FDA information and manufacturer announcements.
Comprehensive Approaches and New Horizons in Managing Vitiligo
Vitiligo treatments are advancing, with proven therapies now joined by a new class of medicines called JAK inhibitors. Vitiligo is an autoimmune condition in which the immune system attacks melanocytes, the cells that give skin its color, causing white patches. It is not physically harmful, but it can deeply affect how people feel about themselves. This guide covers what’s new, what’s FDA-approved, and what’s coming next.
For a full explanation of every option, see our guide to vitiligo treatment options.
New Vitiligo Treatments at a Glance (November 2026)
| Treatment | Type | US status for vitiligo |
|---|---|---|
| Ruxolitinib cream (Opzelura) | JAK inhibitor cream | FDA-approved (2022), ages 12+ |
| Upadacitinib (Rinvoq) | JAK inhibitor pill | Under FDA review; approved in the EU in July 2026 |
| Ritlecitinib (Litfulo) | JAK inhibitor pill | Positive phase 3 results (July 2026); FDA filing planned |
| Povorcitinib | JAK inhibitor pill | Positive phase 3 results; FDA filing planned for the first half of 2027 |
| Afamelanotide (Scenesse) | Hormone-like implant used with light therapy | In phase 3 trials; not approved for vitiligo |
| Baricitinib (Olumiant) | JAK inhibitor pill | Not approved for vitiligo |
Ruxolitinib cream is the only FDA-approved treatment for vitiligo. Other treatments below are commonly prescribed by dermatologists but are not specifically FDA-approved for vitiligo.
Traditional Vitiligo Treatments
Managing vitiligo usually aims to stop new patches, restore color, and keep results. These established treatments remain the foundation of care.
Topical Corticosteroids
Corticosteroid creams and ointments are among the most common treatments. They calm inflammation and can help color return. Dermatologists usually prescribe them for a limited time to lower the risk of side effects such as skin thinning.
Topical Calcineurin Inhibitors
Tacrolimus and pimecrolimus (brand name Elidel) are steroid-free creams that calm the immune system in the skin. The AAD notes they tend to work best on the head and neck, which makes them a common choice for the face.
Phototherapy
Light therapy uses ultraviolet (UV) light to help restore color. For large areas, phototherapy is given in a light box; for small areas, a laser such as an excimer laser can target just the affected skin. Light therapy works slowly and needs several treatments, so dermatologists may combine it with a cream. It works best on the face and neck.
Surgical Options
When other treatments do not restore color, surgery such as a skin graft or cell transplant can move healthy pigment cells to white areas. According to the AAD, surgery is usually not recommended if vitiligo has been active (new or growing spots) in the past 12 months, or for people who develop raised scars.
Depigmentation Therapy
For people who have lost most of their skin color, a prescription cream can remove the remaining color to create an even skin tone. The AAD describes this as rarely used; it can take 1 to 4 years and is permanent.
Emerging Medical Treatments
Research into how the immune system attacks pigment cells has led to more targeted treatments. The biggest change is the JAK inhibitors described below, but other approaches are also being studied.
Antioxidants and Adjunctive Therapies
You may see claims that vitamins, minerals or other supplements restore skin color. According to the AAD, researchers are studying them, but more research is needed to know whether any diet or supplement can effectively treat vitiligo. Talk with your dermatologist before starting one.
Other Systemic Immunomodulators
When vitiligo is spreading quickly, a dermatologist may prescribe a short course of a corticosteroid pill such as prednisone to help slow it down.
Afamelanotide (Scenesse) takes a different approach: instead of calming the immune system, it copies a natural hormone that tells pigment cells to make pigment. It is FDA-approved for a rare light-sensitivity condition, not for vitiligo. Its maker, Clinuvel, expects first results from a phase 3 vitiligo trial (afamelanotide plus light therapy versus light therapy alone) in the second half of 2026.
The Promise of JAK Inhibitors in Vitiligo Treatment
JAK inhibitors are the most important advance in vitiligo treatment in recent years. They come as a cream applied to the skin or as pills that treat the whole body.
How JAK Inhibitors Work
JAK (Janus kinase) enzymes carry signals that drive inflammation. In vitiligo, overactive JAK signaling is believed to fuel the immune attack on pigment cells. JAK inhibitors block these signals, which can stop the attack and let color return.
Clinical Evidence and Approvals
- Ruxolitinib cream (Opzelura): FDA-approved in July 2022 for nonsegmental vitiligo in people 12 and older, on up to 10% of the body. In phase 3 trials, about 30% of patients regained at least 75% of facial color at week 24, and about 50% by week 52.
- Upadacitinib (Rinvoq): approved in the European Union in July 2026 and under FDA review. In the Viti-Up phase 3 trials, 28% to 33% of patients regained at least 75% of facial color at week 48.
- Ritlecitinib (Litfulo): Pfizer reported in July 2026 that two phase 3 vitiligo trials met their main goals at week 52 and plans to file for FDA approval for adults.
- Povorcitinib: about 19% of patients regained at least 75% of facial color at week 52 in two phase 3 trials, compared with 3% to 7% on placebo. Incyte plans to file in the first half of 2027.
Read more about each medicine in our guide to JAK inhibitors for vitiligo.
Oral Medication for Vitiligo
No pill is FDA-approved for vitiligo yet. Rinvoq is the closest, with approval in Europe and an FDA decision pending, followed by Litfulo and povorcitinib. Until then, the only pill dermatologists commonly use for vitiligo is a short course of a steroid such as prednisone for fast-spreading disease. Olumiant (baricitinib) is a JAK pill approved for other conditions but not for vitiligo.
Advantages and Considerations
- JAK inhibitors target the immune process behind vitiligo rather than only covering patches.
- They do not work for everyone, and results take months.
- With ruxolitinib cream, the most common side effects in trials were acne or itching where it was applied, cold symptoms, headache, urinary tract infection, redness and fever.
- All JAK inhibitors carry an FDA boxed warning about serious infections, cancer, heart events and blood clots, so a dermatologist reviews your health history first.
Ongoing Research
Researchers are studying JAK pills for widespread vitiligo, longer-term results, and combinations with light therapy. How color returns, and how to keep it, is explained in our post on vitiligo repigmentation.
Vitiligo Care in North Carolina
Trillium Clinic Dermatology sees patients with vitiligo at our offices in Chapel Hill, Smithfield and Burlington, North Carolina. Our dermatologists can review your options, including new treatments as they become available. Learn more about vitiligo.
Conclusion
Vitiligo treatment is changing. Creams, light therapy and other proven treatments still help many people, ruxolitinib cream is now FDA-approved, and JAK pills for widespread vitiligo are close to approval in the US. There is no cure yet, and about 40% of people lose some restored color within a year of stopping treatment, so ongoing care matters. A dermatologist can help you choose the right plan.
Schedule an appointment at one of our North Carolina offices.
Frequently asked questions
The newest treatments are JAK inhibitors. Ruxolitinib cream (Opzelura) has been FDA-approved since 2022. Upadacitinib (Rinvoq), a pill, was approved for vitiligo in the European Union in July 2026 and is under FDA review, and ritlecitinib and povorcitinib have positive phase 3 results. Afamelanotide is also in phase 3 trials.
Ruxolitinib cream (Opzelura) is the only FDA-approved treatment for vitiligo. It is approved for nonsegmental vitiligo in people 12 and older. Other treatments, such as corticosteroid creams, tacrolimus, pimecrolimus and light therapy, are commonly prescribed but not specifically FDA-approved for vitiligo.
No pill is FDA-approved for vitiligo yet. Rinvoq is under FDA review after its European approval, and Litfulo and povorcitinib have filings planned. A dermatologist may prescribe a short course of a steroid pill such as prednisone when vitiligo is spreading quickly.
There is no single best cream. Ruxolitinib cream (Opzelura) is the only FDA-approved vitiligo cream. Corticosteroid creams are a common first treatment, and calcineurin inhibitors such as tacrolimus and pimecrolimus (Elidel) work well on the face and neck. A dermatologist can recommend the right cream for where your patches are.
Like all medicines, they have benefits and risks. With ruxolitinib cream, the most common side effects in trials were acne or itching where it was applied, cold symptoms and headache. All JAK inhibitors carry an FDA boxed warning about serious infections, cancer, heart events and blood clots, so a dermatologist reviews your health history first.
Trillium Clinic Dermatology sees patients with vitiligo at our offices in Chapel Hill, Smithfield and Burlington. Schedule an appointment to discuss your options.
About Dr. Weiss
Stefan C. Weiss, MD, FAAD, is a board-certified dermatologist, the medical director of Trillium Clinic and an adjunct professor of dermatology at Brown University. He trained at Duke University School of Medicine and Stanford University Medical Center, has authored more than 100 peer-reviewed abstracts, posters and manuscripts, and has over two decades of experience in medical and cosmetic dermatology.
References
- American Academy of Dermatology. Vitiligo: Diagnosis and treatment.
- Incyte. FDA approval of Opzelura cream for vitiligo. July 18, 2022.
- AbbVie. European Commission approval of Rinvoq for non-segmental vitiligo. July 29, 2026.
- Pfizer. Positive topline phase 3 results for Litfulo in nonsegmental vitiligo. July 30, 2026.
- Incyte. First quarter 2026 results and business update. April 2026.
- Clinuvel. CUV105 phase 3 vitiligo trial. May 7, 2025.
- U.S. Food and Drug Administration. JAK inhibitors: drug safety communication. 2021.
This article is for general education and isn’t a substitute for personal medical advice. A dermatologist can tell you which treatment is right for you.

